Grace Therapeutics Inc

For the period ended Mar 31, 2025. Filed Jun 23, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Jun 23, 2025

GRCE$1.86-0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

	Common stock
(Expressed in thousands except share data)	Number	Amount	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit	Total stockholders' equity
$ · $ · $ · $ · $
Balance, March 31, 2024	9,399,404	1	278,899	(6,038)	(211,119)	61,743
Issuance of common stock upon cashless exercise of pre-funded warrants	740,457	—	—	—	—	—
Net loss	—	—	—	—	(9,568)	(9,568)
Stock-based compensation	—	—	730	—	—	730
Issuance of common stock and warrants through private placement, net of offering costs	3,252,132	—	13,705	—	—	13,705
Issuance of common stock in exercise of pre-funded warrants	326,113	—	—	—	—	—
Balance at March 31, 2025	13,718,106	1	293,334	(6,038)	(220,687)	66,610

	Common stock
(Expressed in thousands except share data)	Number	Amount	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit	Total stockholders' equity
$ · $ · $ · $ · $
Balance, March 31, 2023	7,435,533	1	272,259	(6,038)	(198,266)	67,955
Net loss	—	—	—	—	(12,853)	(12,853)
Stock-based compensation	—	—	913	—	—	913
Issuance of common stock and pre-funded warrants through private placement, net of offering costs	1,951,371	—	5,707	—	—	5,707
Issuance of common stock upon the exercise of stock options	12,500	—	21	—	—	21
Balance at March 31, 2024	9,399,404	1	278,899	(6,038)	(211,119)	61,743

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.